---
title: 1,4-ä¸äºŒé†‡
description: 
published: true
date: 2026-01-30T09:13:10.298Z
tags: 
editor: markdown
dateCreated: 2026-01-30T05:53:11.975Z
---

# 1,4-ä¸äºŒé†‡

[â—€è¿”å›](/è¯ç‰©/home.md)



| | |
|--|-- |
|![Skull and crossbones darktextred2.png](/æ–‡ä»¶/Skull_and_crossbones_darktextred2.png)|**å½“[GABAç±»ç‰©è´¨](/æ–‡æ¡£/GABA.md#GABA_receptors)ï¼ˆGABAï¼‰ä¸å…¶ä»–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)å¦‚[é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)ã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)ã€[å·´æ¯”å¦¥ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md)ã€[åŠ å·´å–·ä¸ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/åŠ å·´å–·ä¸ç±»ç‰©è´¨.md)ã€[å™»å©äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å™»å©äºŒæ°®å“ç±»ç‰©è´¨.md)æˆ–[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)è”ç”¨æ—¶ï¼Œå¯èƒ½ä¼šå¯¼è‡´è‡´å‘½çš„[è¯ç‰©è¿‡é‡](/æ–‡æ¡£/è¯ç‰©è¿‡é‡.md)ã€‚[\[1\]](#cite_note-tripsit-1)**|

å¼ºçƒˆä¸å»ºè®®å°†è¿™äº›ç‰©è´¨è”ç”¨ï¼Œå°¤å…¶æ˜¯åœ¨[ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸­ç­‰)åˆ°[ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸¥é‡)å‰‚é‡ä¸‹ã€‚

| *[æ€»ç»“è¡¨: 1,4-ä¸äºŒé†‡](/è¯ç‰©/1,4-ä¸äºŒé†‡.md)* |
| --- |

| 1,4-ä¸äºŒé†‡ | |
| --- | --- |
| [![1,4-Butanediol.png](/æ–‡ä»¶/1,4-Butanediol.png)](/æ–‡ä»¶/1,4-Butanediol.png) | |
| **åŒ–å­¦å‘½å** | |
| å¸¸ç”¨å | *1,4-Butanediol, 1,4-B, BD, BDO, One Comma Four, One Four Bee, Butylene Glycol, or One Four B-D-O* |
| ç³»ç»Ÿå‘½å | *Butane-1,4-diol* |
| **åˆ†ç±»** | |
| ç²¾ç¥è¯æ•ˆç±» | *[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)* |
| åŒ–å­¦ç»“æ„ç±» | *[çƒ·äºŒé†‡](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/çƒ·äºŒé†‡.md)* |
| **[ç»™è¯é€”å¾„](/æ–‡æ¡£/ç»™è¯é€”å¾„.md)** | |
| - **è­¦å‘Šï¼š** ç”±äºä¸ªä½“ä½“é‡ã€è€å—æ€§ã€ä»£è°¢å’Œä¸ªäººæ•æ„Ÿåº¦çš„å·®å¼‚ï¼Œè¯·åŠ¡å¿…ä»ä½å‰‚é‡å¼€å§‹ã€‚[å‚è§è´Ÿè´£ä»»çš„ç”¨è¯éƒ¨åˆ†](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚ | |

### [ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md) (â‡£ [å£æœ](/æ–‡æ¡£/ç»™è¯é€”å¾„.md#å£æœ))

| | |
| --- | --- |
| [é˜ˆå€¼](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#é˜ˆå€¼) | < 0.5 mL |
| [è½»å¾®](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#è½»å¾®) | 0.5 - 1 mL |
| [ä¸­ç­‰](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸­ç­‰) | 1 - 2.5 mL |
| [å¼ºçƒˆ](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#å¼ºçƒˆ) | 2.5 - 4 mL |
| [ä¸¥é‡](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md#ä¸¥é‡) | 4 mL + <br>**è­¦å‘Šï¼š4 mL ä»¥ä¸Šçš„å‰‚é‡å¯è¯±å‘æ·±åº¦ç¡çœ ï¼Œ6 mL ä»¥ä¸Šçš„å‰‚é‡å¯å¯¼è‡´ä¸­æ¯’[\[2\]](#cite_note-cite-2)** |

### [è¯æ•ˆæ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md)

| | |
| --- | --- |
| [æ€»æ—¶é•¿](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#æ€»æ—¶é•¿) | 3 - 5 å°æ—¶ |
| [è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆå‘ä½œ) | 20 - 60 åˆ†é’Ÿ |
| [è¯æ•ˆè¾¾å³°](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¾¾å³°) | 1 - 2 å°æ—¶ |
| [è¯æ•ˆè¤ªå»](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆè¤ªå») | 1.5 - 2 å°æ—¶ |
| [è¯æ•ˆæ®‹ä½™](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆæ®‹ä½™) | 2 - 4 å°æ—¶ |

- **[å…è´£å£°æ˜](/å…³äºæœ¬ç«™/å…è´£å£°æ˜.md)ï¼š** FreeODwikiçš„[ç»™è¯å‰‚é‡](/æ–‡æ¡£/ç»™è¯å‰‚é‡.md)ä¿¡æ¯æ”¶é›†è‡ªç”¨æˆ·å’Œ[èµ„æº](/å…³äºæœ¬ç«™/ç½‘ç»œèµ„æº.md)ï¼Œä»…ç”¨äºæ•™è‚²ç›®çš„ã€‚å®ƒä¸æ˜¯æ¨èï¼Œåº”ä¸å…¶ä»–æ¥æºæ ¸å®ä»¥ç¡®ä¿å‡†ç¡®æ€§ã€‚

| **[è¯ç‰©è”ç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)** | |
| --- | --- |
| [å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md) | âš ï¸ **è°¨æ…è”ç”¨** |
| [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md) | ğŸ’” **è”ç”¨å±é™©** |
| [è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md) | ğŸ’” **è”ç”¨å±é™©** |


**1,4-ä¸äºŒé†‡**ï¼ˆä¹Ÿç§°ä¸º **1,4-B**ã€**BDO**ã€**BD æˆ– 1,4-BD**ï¼‰æ˜¯ä¸€ç§[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)ç‰©è´¨ï¼Œä¹Ÿæ˜¯[GHB](/è¯ç‰©/GHB.md)çš„[å‰è¯](/æ–‡æ¡£/è¯ç‰©å‰è¯.md)ã€‚å®ƒæ˜¯ä¸€ç§ç²˜ç¨ ã€æ— è‰²çš„æ¶²ä½“æˆ–å›ºä½“ï¼Œå…·ä½“å–å†³äºå‚¨å­˜æ¸©åº¦ï¼ˆç†”ç‚¹ä¸º 20 â„ƒï¼‰ï¼Œå…·æœ‰ç‹¬ç‰¹çš„è‹¦ç”œå‘³ã€‚[\[3\]](#cite_note-3) å®ƒè¢«ç”¨ä½œå¨±ä¹æ€§è‡´é†‰å‰‚ï¼Œæ•ˆæœç±»ä¼¼äº[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)å’Œ[GHB](/è¯ç‰©/GHB.md)ã€‚[\[4\]](#cite_note-4) 1 ml çš„ 1,4-ä¸äºŒé†‡ç›¸å½“äº 1.4 g çš„ Na-GHBã€‚

1,4-ä¸äºŒé†‡åœ¨å·¥ä¸šä¸Šç”¨ä½œæº¶å‰‚ï¼Œä»¥åŠåˆ¶é€ æŸäº›ç±»å‹çš„å¡‘æ–™ã€å¼¹æ€§çº¤ç»´å’Œèšæ°¨é…¯ã€‚åœ¨æœ‰æœºåŒ–å­¦ä¸­ï¼Œå®ƒç”¨äºåˆæˆ[Î³-ä¸å†…é…¯ (GBL)](/è¯ç‰©/GBL.md)ã€‚[\[5\]](#cite_note-5)

1,4-ä¸äºŒé†‡ä»¥åŠ[GBL](/è¯ç‰©/GBL.md)ä¼šéšç€æ—¶é—´çš„æ¨ç§»æº¶è§£å¤§å¤šæ•°ç±»å‹çš„å¡‘æ–™ã€‚[\[6\]](#cite_note-6) å› æ­¤ï¼Œå»ºè®®ä»…ä½¿ç”¨ç»ç’ƒå®¹å™¨ã€æ ‡å‡†æ˜èƒ¶èƒ¶å›Šï¼ˆéç´ é£Ÿï¼‰æˆ–é«˜å¯†åº¦èšä¹™çƒ¯å¡‘æ–™ï¼ˆä¹Ÿç§°ä¸º #2 å›æ”¶å¡‘æ–™ï¼‰æ¥è¿è¾“å’Œå‚¨å­˜è¯¥è¯ç‰©ã€‚è¦æ£€æŸ¥ç“¶å­ä½¿ç”¨çš„å¡‘æ–™ç±»å‹ï¼Œå¯ä»¥æŸ¥çœ‹åº•éƒ¨ä¸‰è§’å½¢å›æ”¶æ ‡ç­¾ä¸­çš„æ•°å­—ã€‚

ç›®å½•
--------

* [1 åŒ–å­¦](#åŒ–å­¦)
* [2 è¯ç†å­¦](#è¯ç†å­¦)
* [3 ä¸»è§‚æ•ˆåº”](#ä¸»è§‚æ•ˆåº”)
    + [3.1 **ç‰©ç†æ•ˆåº”**](#ç‰©ç†æ•ˆåº”)
    + [3.2 **è®¤çŸ¥æ•ˆåº”**](#è®¤çŸ¥æ•ˆåº”)
    + [3.3 ä½“éªŒæŠ¥å‘Š](#ä½“éªŒæŠ¥å‘Š)
* [4 æ¯’æ€§å’Œå±å®³æ½œåŠ›](#æ¯’æ€§å’Œå±å®³æ½œåŠ›)
    + [4.1 ç¥ç»æ¯’æ€§](#ç¥ç»æ¯’æ€§)
    + [4.2 è€å—æ€§å’Œæˆç˜¾æ½œåŠ›](#è€å—æ€§å’Œæˆç˜¾æ½œåŠ›)
    + [4.3 å±é™©çš„ç›¸äº’ä½œç”¨](#å±é™©çš„ç›¸äº’ä½œç”¨)
* [5 æ³•å¾‹åœ°ä½](#æ³•å¾‹åœ°ä½)
* [6 å¦è§](#å¦è§)
* [7 å¤–éƒ¨é“¾æ¥](#å¤–éƒ¨é“¾æ¥)
* [8 å‚è€ƒæ–‡çŒ®](#å‚è€ƒæ–‡çŒ®)

åŒ–å­¦
---------

1,4-ä¸äºŒé†‡è¢«å½’ç±»ä¸ºä¸€ç§ç§°ä¸º[äºŒé†‡](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/çƒ·äºŒé†‡.md)çš„é†‡ç±»åŒ–åˆç‰©äºšç±»ã€‚äºŒé†‡å› å…¶ç»“æ„ä¸­æœ‰ä¸¤ä¸ªé†‡ (OH-) å–ä»£åŸºè€Œå¾—åã€‚1,4-ä¸äºŒé†‡ç”±å››ä¸ªç¢³åŸºå›¢ç»„æˆçš„ä¸çƒ·é“¾ç»„æˆï¼Œä¸€ä¸ªé†‡åŸºå›¢ç»“åˆåœ¨è¯¥é“¾çš„æ¯ä¸ªæœ«ç«¯ç¢³ä¸Šã€‚1,4-ä¸äºŒé†‡å› è¿™äº›ä½äº R1 å’Œ R4 çš„é†‡å–ä»£åŸºè€Œå¾—åã€‚è¿™äº›é†‡å–ä»£åŸºä½¿ 1,4-ä¸äºŒé†‡æˆä¸ºææ€§æ¶²ä½“ï¼Œè¿™è§£é‡Šäº†å…¶è‰¯å¥½çš„æ°´æº¶æ€§ã€‚

åœ¨ç‰©ç†ä¸Šï¼Œå®ƒæ˜¯ä¸€ç§å¸æ¹¿æ€§æ— è‰²æ²¹çŠ¶æ¶²ä½“ï¼Œå‡ ä¹æ²¡æœ‰ç‰¹å¾æ°”å‘³ã€‚ä¸ GHB ä¸åŒï¼Œ1,4-ä¸äºŒé†‡å…·æœ‰ç‹¬ç‰¹çš„å‘³é“ï¼Œè¢«æè¿°ä¸ºä»¤äººåæ„Ÿã€ç±»ä¼¼å¡‘æ–™å’ŒåŒ–å­¦å“çš„å‘³é“ã€‚

è¯ç†å­¦
------------

ä¸»æ¡ç›®ï¼š[GHB Â§ è¯ç†å­¦](/è¯ç‰©/GHB.md#Pharmacology)

1,4-ä¸äºŒé†‡æœ¬èº«æ²¡æœ‰æ´»æ€§ï¼›å…¶ä½œç”¨æœºåˆ¶æºäºå…¶ä½œä¸º[GHB](/è¯ç‰©/GHB.md)[å‰è¯](/æ–‡æ¡£/è¯ç‰©å‰è¯.md)çš„èº«ä»½ã€‚[\[7\]](#cite_note-7)

å®ƒåœ¨è‚è„ä¸­é€šè¿‡ä¹™é†‡è„±æ°¢é…¶å’Œä¹™é†›è„±æ°¢é…¶è½¬åŒ–ä¸º GHBï¼Œè¿™ä¸ä»£è°¢[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)çš„é…¶ç›¸åŒã€‚[\[8\]](#cite_note-8) 1,4-ä¸äºŒé†‡é¦–å…ˆåœ¨è‚è„ä¸­è½¬åŒ–ä¸º 4-ç¾ŸåŸºä¸é†›å¹¶é‡Šæ”¾åˆ°è¡€æ¶²ä¸­ï¼Œç„¶åè¿”å›è‚è„è½¬åŒ–ä¸º[GHB](/è¯ç‰©/GHB.md)ã€‚è¿™ä¸ªè¿‡ç¨‹å¯¼è‡´å…¶[è¯æ•ˆå‘ä½œ](/æ–‡æ¡£/è¯æ•ˆæ—¶é•¿.md#è¯æ•ˆå‘ä½œ)æ¯”[GBL](/è¯ç‰©/GBL.md)æˆ–[GHB](/è¯ç‰©/GHB.md)å»¶è¿Ÿå¾—å¤šã€‚[\[9\]](#cite_note-9) 4-ç¾ŸåŸºä¸é†›è™½ç„¶æ˜¯ä¸€ç§é†›ï¼Œä½†ä¸å…·æœ‰ä¸ä¹™é†›ç›¸åŒçš„å™¨å®˜æ¯’æ€§ã€‚[\[10\]](#cite_note-10) ä¸€ä¸ªåŸå› å¯èƒ½æ˜¯å…¶å‘ GHB çš„ä»£è°¢éå¸¸å¿«ã€‚

[![](/æ–‡ä»¶/GHB_Prodrugs_metabolic_Pathways.png)](/æ–‡ä»¶/GHB_Prodrugs_metabolic_Pathways.png)

[](/wiki/File:GHB_Prodrugs_metabolic_Pathways.png "æ”¾å¤§")

GBL å’Œ 1,4-ä¸äºŒé†‡ä½œä¸º GHB å‰è¯çš„ä»£è°¢é€”å¾„

è„±æ°¢é…¶æ°´å¹³çš„å·®å¼‚å› äººè€Œå¼‚ï¼Œè¿™æ„å‘³ç€å°±åƒé…’ç²¾ä¸€æ ·ï¼Œä¸åŒä½¿ç”¨è€…çš„æ•ˆæœå¯èƒ½å·®å¼‚å¾ˆå¤§ã€‚åœ¨è®¸å¤šäººä¸­ï¼Œè¿™è¡¨ç°ä¸ºè¯æ•ˆå‘ä½œç¼“æ…¢å’Œé†›åœ¨è¡€æ¶²ä¸­ç§¯èšç‡è¾ƒé«˜ï¼Œä»è€Œå¼•èµ·æ›´å¤šçš„æ¯’å‰¯ä½œç”¨ã€‚ç”±äºè¿™äº›è¯ä»£åŠ¨åŠ›å­¦çš„å·®å¼‚ï¼Œ1,4-ä¸äºŒé†‡å¾€å¾€æ¯” GHB æ•ˆåŠ›ä½ä¸”èµ·æ•ˆæ…¢ï¼Œä½†æŒç»­æ—¶é—´æ›´é•¿ï¼›ç›¸å…³åŒ–åˆç‰©[GBL](/è¯ç‰©/GBL.md)å¾€å¾€æ¯” GHB æ•ˆåŠ›ç¨é«˜ä¸”èµ·æ•ˆæ›´å¿«ï¼Œä½†ä½œç”¨æ—¶é—´æ›´çŸ­ã€‚

ä¸»è§‚æ•ˆåº”
------------------

[![](/æ–‡ä»¶/1,4_Butanediol_pic.jpg)](/æ–‡ä»¶/1,4_Butanediol_pic.jpg)

[](/wiki/File:1,4_Butanediol_pic.jpg "æ”¾å¤§")

ä¸€ç“¶ 1,4-ä¸äºŒé†‡ã€‚

***å…è´£å£°æ˜**ï¼šä¸‹åˆ—æ•ˆåº”åˆ—è¡¨å‚è€ƒäº†[***ä¸»è§‚æ•ˆåº”ç´¢å¼•***](/è¯æ•ˆ/home.md) (**SEI**)ï¼Œè¿™æ˜¯ä¸€ä¸ªåŸºäºä¼ é—»ä¸­çš„ç”¨æˆ·æŠ¥å‘Šå’Œ[PsychonautWiki](/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md) [è´¡çŒ®è€…](/å…³äºæœ¬ç«™/å…³äºFreeODwiki.md)çš„ä¸ªäººåˆ†æçš„å¼€æ”¾ç ”ç©¶æ–‡çŒ®ã€‚å› æ­¤ï¼Œåº”ä»¥å¥åº·çš„æ€€ç–‘æ€åº¦çœ‹å¾…å®ƒä»¬ã€‚*

*åŒæ ·å€¼å¾—æ³¨æ„çš„æ˜¯ï¼Œè¿™äº›æ•ˆåº”ä¸ä¸€å®šä¼šä»¥å¯é¢„æµ‹æˆ–å¯é çš„æ–¹å¼å‘ç”Ÿï¼Œå°½ç®¡è¾ƒé«˜çš„å‰‚é‡æ›´å¯èƒ½è¯±å‘å…¨æ–¹ä½çš„æ•ˆåº”ã€‚*åŒæ ·ï¼Œ**ä¸è‰¯ååº”**åœ¨è¾ƒé«˜å‰‚é‡ä¸‹å˜å¾—è¶Šæ¥è¶Šå¯èƒ½ï¼Œå¹¶ä¸”å¯èƒ½åŒ…æ‹¬**æˆç˜¾ã€ä¸¥é‡ä¼¤å®³æˆ–æ­»äº¡** â˜ ã€‚

### **[èº¯ä½“æ•ˆåº”](/è¯æ•ˆ/èº¯ä½“æ•ˆåº”.md)** ![Child.png](/æ–‡ä»¶/Child.png)

*     + **[åˆºæ¿€](/è¯æ•ˆ/åˆºæ¿€.md)** å’Œ **[é•‡é™](/è¯æ•ˆ/é•‡é™.md)** - åœ¨è¾ƒä½å‰‚é‡ä¸‹ï¼Œ1,4-ä¸äºŒé†‡åœ¨ç‰©ç†ä¸Šå…·æœ‰åˆºæ¿€æ€§ï¼Œé¼“åŠ±è¿åŠ¨å’Œæ¸…é†’ã€‚ç„¶è€Œï¼Œåœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒä¼šäº§ç”Ÿç‰©ç†é•‡é™ä½œç”¨ï¼Œé¼“åŠ±ç¡çœ å’Œå—œç¡ã€‚
    + **[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)** - åœ¨ 1,4-ä¸äºŒé†‡è¿‡é‡çš„æƒ…å†µä¸‹ï¼Œæ®æŠ¥é“è®¸å¤šäººä¼šå‡ºç°å¼‚å¸¸çš„å‘¼å¸æ¨¡å¼ï¼Œç‰¹å¾æ˜¯å‘¼å¸é€æ¸åŠ æ·±ï¼Œæœ‰æ—¶åŠ å¿«ï¼Œéšåé€æ¸å‡æ…¢ï¼Œå¯¼è‡´å‘¼å¸æš‚æ—¶åœæ­¢ï¼Œç§°ä¸ºå‘¼å¸æš‚åœã€‚
    + **[èº¯ä½“æ¬£å¿«æ„Ÿ](/è¯æ•ˆ/èº¯ä½“æ¬£å¿«æ„Ÿ.md)**
    + **[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md)** - è¿™ç§æ•ˆåº”åœ¨ 1,4-ä¸äºŒé†‡ä¸­æ¯”[GHB](/è¯ç‰©/GHB.md)æ›´å¸¸è§ã€‚
    + **[èƒƒç—‰æŒ›](/è¯æ•ˆ/èƒƒç—‰æŒ›.md)**
    + **[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)**
    + **[å¤´æ™•](/è¯æ•ˆ/å¤´æ™•.md)**
    + **[è„±æ°´](/è¯æ•ˆ/è„±æ°´.md)** - è¿™ç§æ•ˆåº”ä¸ 1,4-ä¸äºŒé†‡çš„å¸æ¹¿æ€§æœ‰å…³ã€‚
    + **[è‚Œè‚‰ç—‰æŒ›](/è¯æ•ˆ/è‚Œè‚‰ç—‰æŒ›.md)**
    + **[çœ¼çƒæ»‘åŠ¨](/è¯æ•ˆ/çœ¼çƒæ»‘åŠ¨.md)**
    + **[æµæ¶/ç—°æ¶²å¢å¤š](/è¯æ•ˆ/ç—°æ¶²å¢å¤š.md)**

### **[è®¤çŸ¥æ•ˆåº”](/è¯æ•ˆ/è®¤çŸ¥æ•ˆåº”.md)** ![User.png](/æ–‡ä»¶/User.png)

*     + **[ç„¦è™‘æŠ‘åˆ¶](/è¯æ•ˆ/ç„¦è™‘æŠ‘åˆ¶.md)**
    + **[å»æŠ‘åˆ¶](/è¯æ•ˆ/å»æŠ‘åˆ¶.md)**
    + **[è®¤çŸ¥æ¬£å¿«](/è¯æ•ˆ/è®¤çŸ¥æ¬£å¿«.md)**
    + **[ç§»æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º](/è¯æ•ˆ/ç§»æƒ…ã€æƒ…æ„Ÿå’Œç¤¾äº¤èƒ½åŠ›å¢å¼º.md)** - ä¸ä»…é€šè¿‡[å»æŠ‘åˆ¶](/è¯æ•ˆ/å»æŠ‘åˆ¶.md)å¢åŠ ç¤¾äº¤èƒ½åŠ›çš„[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)ä¸åŒï¼Œ1,4-ä¸äºŒé†‡å‘ˆç°å‡ºå¼ºçƒˆçš„[å…±æƒ…å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…±æƒ…å‰‚.md)æ•ˆåº”ï¼Œè¿™ç§æ•ˆåº”æ˜¾è‘—ä¸”æ˜ç¡®ï¼Œè™½ç„¶æ¯”[MDMA](/è¯ç‰©/MDMA.md)å¼±ã€‚
    + **[åˆ†æèƒ½åŠ›æŠ‘åˆ¶](/è¯æ•ˆ/åˆ†æèƒ½åŠ›æŠ‘åˆ¶.md)**
    + **[æ€ç»´å‡é€Ÿ](/è¯æ•ˆ/æ€ç»´å‡é€Ÿ.md)**
    + **[å¥å¿˜](/è¯æ•ˆ/å¤±å¿†.md)**
    + **[æš—ç¤ºæ€§å¢å¼º](/è¯æ•ˆ/æš—ç¤ºæ€§å¢å¼º.md)**
    + **[æ€§æ¬²å¢å¼º](/è¯æ•ˆ/æ€§æ¬²å¢å¼º.md)**
    + **[éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º](/è¯æ•ˆ/éŸ³ä¹æ¬£èµèƒ½åŠ›å¢å¼º.md)**

### ä½“éªŒæŠ¥å‘Š

æè¿°æ­¤åŒ–åˆç‰©åœ¨æˆ‘ä»¬[ä½“éªŒç´¢å¼•](/æ–‡æ¡£/ç§‘å­¦ä¿¡æ¯ç´¢å¼•é¡µ.md)ä¸­çš„æ•ˆæœçš„è½¶äº‹æŠ¥å‘ŠåŒ…æ‹¬ï¼š

* [ä½“éªŒ:2ml 1,4-ä¸äºŒé†‡ - ä¸å¦‚é…’ç²¾å¥½](/æŠ¥å‘Š/psychounautwiki/Experience:2ml%201,4-Butanediol%20-%20Not%20as%20good%20as%20alcohol.md)


å…¶ä»–ä½“éªŒæŠ¥å‘Šå¯ä»¥åœ¨è¿™é‡Œæ‰¾åˆ°ï¼š

* [Erowid Experience Vaults: 1,4-Butanediol](https://www.erowid.org/experiences/subs/exp_14Butanediol.shtml)


æ¯’æ€§å’Œå±å®³æ½œåŠ›
---------------------------

ä¸»æ¡ç›®ï¼š[GHB Â§ æ¯’æ€§å’Œå±å®³æ½œåŠ›](/è¯ç‰©/GHB.md#Toxicity_and_harm_potential)

[![](/æ–‡ä»¶/Harmchart.png)](/æ–‡ä»¶/Harmchart.png)

[](/wiki/File:Harmchart.png "æ”¾å¤§")

æ˜¾ç¤º[GHB](/è¯ç‰©/GHB.md)çš„ç›¸å¯¹èº«ä½“ä¼¤å®³ã€ç¤¾ä¼šä¼¤å®³å’Œä¾èµ–æ€§çš„é›·è¾¾å›¾[\[11\]](#cite_note-11)

1,4-ä¸äºŒé†‡æœ¬èº«æ²¡æœ‰æ´»æ€§ï¼›å…¶ä½œç”¨æœºåˆ¶æºäºå…¶ä½œä¸º GHB å‰è¯çš„èº«ä»½ï¼Œè¿™æ„å‘³ç€å®ƒåœ¨ä½“å†…è¿…é€Ÿè½¬åŒ–ä¸º GHBã€‚

å½“è´Ÿè´£ä»»åœ°æˆ–åœ¨åŒ»ç–—ä¸Šä½¿ç”¨æ—¶ï¼ŒGHB è¢«è®¤ä¸ºæ˜¯å®‰å…¨ä¸”æ— æ¯’çš„ç‰©è´¨ã€‚[LD50](/æ–‡æ¡£/è¯ç‰©å‰‚é‡åˆ†ç±».md)é«˜äºæ´»æ€§å‰‚é‡ï¼Œå½“ä»¥é€‚å½“å‰‚é‡æœç”¨è¯¥åŒ–åˆç‰©æ—¶ï¼Œæ²¡æœ‰æ€¥æ€§ä¸­æ¯’çš„å±é™©ã€‚ç„¶è€Œï¼Œå½“ä½œä¸ºå¨±ä¹æ€§è¯ç‰©ä½¿ç”¨æˆ–æ»¥ç”¨æ—¶ï¼Œå®ƒå¯èƒ½æ˜¯å±é™©çš„ã€‚æœ‰è®¸å¤šæ¥è‡ªå¨±ä¹æ€§ç”¨æˆ·çš„è´Ÿé¢æŠ¥å‘Šï¼Œä»–ä»¬ç»å†äº†è¯ç‰©è¿‡é‡ã€å°† GHB ä¸é…’ç²¾æˆ–å…¶ä»–è¯ç‰©æ··åˆã€æˆ–æ„å¤–åœ°ç»™è‡ªå·±æœç”¨äº†æ„æ–™ä¹‹å¤–çš„å‰‚é‡ã€‚[\[12\]](#cite_note-12)

ä¸€ä»½å‡ºç‰ˆç‰©è°ƒæŸ¥äº† 226 ä¾‹å½’å› äº GHB çš„æ­»äº¡ã€‚[\[13\]](#cite_note-13) 71 ä¾‹æ­»äº¡ (34%) æ˜¯ç”±å•ç‹¬ä½¿ç”¨ GHB å¼•èµ·çš„ï¼Œè€Œå…¶ä»–æ­»äº¡æ˜¯ç”±ä¸é…’ç²¾æˆ–å…¶ä»–è¯ç‰©ç›¸äº’ä½œç”¨å¼•èµ·çš„[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚

ä¸ºé¿å… GHB/1,4-ä¸äºŒé†‡å¯èƒ½å‘ç”Ÿçš„è¿‡é‡ï¼Œé‡è¦çš„æ˜¯ä»ä½å‰‚é‡å¼€å§‹ï¼Œå¹¶ä»¥å°å¹…åº¦é€æ¸å¢åŠ å‰‚é‡ï¼Œå› ä¸ºç¡®åˆ‡çš„ä¸­æ¯’å‰‚é‡å°šä¸æ¸…æ¥šã€‚

ç”±äºå‚¨å­˜æ–¹æ³•ä¸å½“ï¼Œä¹Ÿå‘ç”Ÿè¿‡æ„å¤–æ‘„å…¥ 1,4-ä¸äºŒé†‡çš„æƒ…å†µã€‚å¦‚æœå°† 1,4-ä¸äºŒé†‡æ”¾å…¥é€æ˜æ¶²ä½“ã€ç»ç’ƒæ¯æˆ–ç“¶å­ä¸­ï¼Œå¾ˆå®¹æ˜“è¢«è¯¯è®¤ä¸ºæ˜¯æ°´ã€‚å»ºè®®ç”¨æ–‡å­—æ¸…æ¥šåœ°æ ‡è®°æ‚¨çš„ 1,4-ä¸äºŒé†‡ï¼Œå¹¶ç”¨è“è‰²é£Ÿç”¨è‰²ç´ ç»™æ¶²ä½“æŸ“è‰²ï¼Œä½¿å…¶ä¸å†åƒå¯é¥®ç”¨çš„é¥®æ–™ã€‚è¿˜å»ºè®®å°†æ‚¨çš„ 1,4-ä¸äºŒé†‡å‚¨å­˜åœ¨æ²¡æœ‰äººä¼šé¥®ç”¨çš„å®¹å™¨ä¸­ã€‚

å¼ºçƒˆå»ºè®®åœ¨ä½¿ç”¨è¯¥è¯ç‰©æ—¶é‡‡å–[ä¼¤å®³å‡å°‘æªæ–½](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)ã€‚

### ç¥ç»æ¯’æ€§

åœ¨å¤šé¡¹ç ”ç©¶ä¸­ï¼Œå‘ç°é•¿æœŸæœç”¨ GHB ä¼šæŸå®³å¤§é¼ çš„ç©ºé—´è®°å¿†ã€å·¥ä½œè®°å¿†ã€å­¦ä¹ å’Œè®°å¿†èƒ½åŠ›ã€‚[\[14\]](#cite_note-14)[\[15\]](#cite_note-15)[\[16\]](#cite_note-16)[\[17\]](#cite_note-17) è¿™äº›æ•ˆåº”ä¸å¤§è„‘çš®å±‚åŠå¯èƒ½å…¶ä»–åŒºåŸŸçš„ NMDA å—ä½“è¡¨è¾¾å‡å°‘æœ‰å…³ã€‚[\[18\]](#cite_note-18)

ä¸€é¡¹ç ”ç©¶å‘ç°ï¼Œè¿ç»­ 15 å¤©ç»™å¤§é¼ é‡å¤æœç”¨ GHB ä¼šå¤§å¤§å‡å°‘æµ·é©¬ä½“å’Œå‰é¢å¶çš®å±‚å†…çš„ç¥ç»å…ƒå’Œéç¥ç»å…ƒç»†èƒæ•°é‡ã€‚å‰‚é‡ä¸º 10 mg/kg GHB æ—¶ï¼Œæµ·é©¬ä½“åŒºåŸŸå‡å°‘äº† 61%ï¼Œå‰é¢å¶çš®å±‚å‡å°‘äº† 32%ï¼›å‰‚é‡ä¸º 100 mg/kg æ—¶ï¼Œå®ƒä»¬åˆ†åˆ«å‡å°‘äº† 38% å’Œ 9%ã€‚è¯¥è®ºæ–‡è¯æ˜äº†å¯¹ç¥ç»å…ƒæŸå¤±çš„çŸ›ç›¾æ•ˆåº”ï¼Œè¾ƒä½å‰‚é‡ (10 mg/kg) äº§ç”Ÿæœ€å¤§çš„ç¥ç»æ¯’æ€§ï¼Œè€Œè¾ƒé«˜å‰‚é‡ (100 mg/kg) äº§ç”Ÿçš„ç¥ç»æ¯’æ€§è¾ƒå°ã€‚

### è€å—æ€§å’Œæˆç˜¾æ½œåŠ›

[![](/æ–‡ä»¶/GHBwithdrawal2.png)](/æ–‡ä»¶/GHBwithdrawal2.png)

[](/wiki/File:GHBwithdrawal2.png "æ”¾å¤§")

è¯¥è¡¨æ¯”è¾ƒäº† GHB/1,4-ä¸äºŒé†‡ã€[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)å’Œ[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)çš„æˆ’æ–­ç—‡çŠ¶ã€‚[\[19\]](#cite_note-GHB-19)

GHB/1,4-ä¸äºŒé†‡å…·æœ‰ä¸­åº¦çš„èº«ä½“å’Œå¿ƒç†æˆç˜¾æ€§ã€‚å¦‚æœçªç„¶åœæ­¢ä½¿ç”¨ï¼Œé¢‘ç¹ä½¿ç”¨ GHB/1,4-ä¸äºŒé†‡ä¼šå¯¼è‡´ç±»ä¼¼äºå…¶ä»–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)å¦‚[é…’ç²¾](/è¯ç‰©/é…’ç²¾.md)å’Œ[è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md)å¼•èµ·çš„æˆ’æ–­ç—‡çŠ¶ã€‚[\[20\]](#cite_note-20)[\[21\]](#cite_note-21) è¿™äº›ç—‡çŠ¶ä¼¼ä¹å–å†³äºå‰‚é‡å’Œä½¿ç”¨è¯ç‰©çš„æ—¶é—´é•¿çŸ­ã€‚è½»åº¦è‡³ä¸­åº¦ä½¿ç”¨è€…é€šå¸¸ä¼šå‡ºç°ç„¦è™‘ã€å¤±çœ ã€ç¡çœ ç›¸å…³é—®é¢˜å’Œéœ‡é¢¤ï¼Œè€Œé‡åº¦ä½¿ç”¨ä¼šå¯¼è‡´ä¸¥é‡çš„æˆ’æ–­ç—‡çŠ¶ï¼Œå¦‚è°µå¦„ã€ç²¾ç¥ç—…å’Œå¹»è§‰ã€‚[\[22\]](#cite_note-22)[\[19\]](#cite_note-GHB-19)

å°½ç®¡æœ‰æŠ¥é“ç§° GHB/1,4-ä¸äºŒé†‡æˆ’æ–­å¯¼è‡´æ­»äº¡ï¼Œä½†æŠ¥å‘Šå°šæ— å®šè®ºï¼Œéœ€è¦è¿›ä¸€æ­¥ç ”ç©¶ã€‚[\[23\]](#cite_note-23)

è¿ç»­ä½¿ç”¨å‡ å‘¨åï¼Œä¼šå¯¹é•‡é™å‚¬çœ ä½œç”¨äº§ç”Ÿè€å—æ€§ã€‚åœæ­¢ä½¿ç”¨åï¼Œè€å—æ€§ä¼šåœ¨ 7 - 14 å¤©å†…æ¢å¤åˆ°åŸºçº¿ã€‚åœ¨å‡ å‘¨æˆ–æ›´é•¿æ—¶é—´çš„ç¨³å®šç»™è¯åçªç„¶åœæ­¢ä½¿ç”¨ï¼Œå¯èƒ½ä¼šå‡ºç°æˆ’æ–­ç—‡çŠ¶æˆ–åå¼¹ç—‡çŠ¶ï¼Œå¯èƒ½éœ€è¦é€æ¸å‡å°‘å‰‚é‡ã€‚

### å±é™©çš„ç›¸äº’ä½œç”¨

***è­¦å‘Šï¼š*** *è®¸å¤šç²¾ç¥æ´»æ€§ç‰©è´¨å•ç‹¬ä½¿ç”¨æ—¶ç›¸å¯¹å®‰å…¨ï¼Œä½†ä¸æŸäº›å…¶ä»–ç‰©è´¨ç»“åˆä½¿ç”¨æ—¶ï¼Œå¯èƒ½ä¼šçªç„¶å˜å¾—å±é™©ç”šè‡³å±åŠç”Ÿå‘½ã€‚ä»¥ä¸‹åˆ—è¡¨åˆ—å‡ºäº†ä¸€äº›å·²çŸ¥çš„å±é™©ç›¸äº’ä½œç”¨ï¼ˆå°½ç®¡ä¸ä¿è¯åŒ…æ‹¬æ‰€æœ‰ç›¸äº’ä½œç”¨ï¼‰ã€‚*

*åŠ¡å¿…è¿›è¡Œç‹¬ç«‹ç ”ç©¶ï¼ˆä¾‹å¦‚ [Google](https://www.google.com), [DuckDuckGo](https://www.duckduckgo.com), [PubMed](https://pubmed.ncbi.nlm.nih.gov/)ï¼‰ä»¥ç¡®ä¿ä¸¤ç§æˆ–å¤šç§ç‰©è´¨çš„ç»„åˆå¯ä»¥å®‰å…¨é£Ÿç”¨ã€‚åˆ—å‡ºçš„ä¸€äº›ç›¸äº’ä½œç”¨æ¥è‡ª [TripSit](https://combo.tripsit.me)ã€‚*

* **[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)** (*1,4-ä¸äºŒé†‡, [2M2B](/è¯ç‰©/2M2B.md), [é…’ç²¾](/è¯ç‰©/é…’ç²¾.md), [è‹¯äºŒæ°®å“ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è‹¯äºŒæ°®å“ç±»ç‰©è´¨.md), [å·´æ¯”å¦¥ç±»ç‰©è´¨](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å·´æ¯”å¦¥ç±»ç‰©è´¨.md), [GHB](/è¯ç‰©/GHB.md)/[GBL](/è¯ç‰©/GBL.md), [ç”²å–¹é…®](/è¯ç‰©/ç”²å–¹é…®.md), [é˜¿ç‰‡ç±»è¯ç‰©](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/é˜¿ç‰‡ç±»è¯ç‰©.md)*) - è¿™ç§ç»„åˆä¼šå¢å¼ºå½¼æ­¤å¼•èµ·çš„[è‚Œè‚‰æ¾å¼›](/è¯æ•ˆ/è‚Œè‚‰æ¾å¼›.md)ã€[å¥å¿˜](/è¯æ•ˆ/å¤±å¿†.md)ã€[é•‡é™](/è¯æ•ˆ/é•‡é™.md)å’Œ[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚åœ¨è¾ƒé«˜å‰‚é‡ä¸‹ï¼Œå®ƒä¼šå¯¼è‡´çªç„¶ã€æ„å¤–çš„æ„è¯†ä¸§å¤±ä»¥åŠå±é™©ç¨‹åº¦çš„å‘¼å¸æŠ‘åˆ¶ã€‚åœ¨æ— æ„è¯†æ—¶è¢«å‘•åç‰©çª’æ¯çš„é£é™©ä¹Ÿä¼šå¢åŠ ã€‚å¦‚æœåœ¨æ„è¯†ä¸§å¤±ä¹‹å‰å‘ç”Ÿ[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md)æˆ–å‘•åï¼Œä½¿ç”¨è€…åº”å°è¯•ä»¥[æ¢å¤ä½“ä½](/æ–‡æ¡£/æ¢å¤ä½“ä½.md)å…¥ç¡æˆ–è®©æœ‹å‹å°†å…¶ç§»å…¥è¯¥ä½“ä½ã€‚
* **[è§£ç¦»å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/è§£ç¦»å‰‚.md)** - è¿™ç§ç»„åˆå¯èƒ½ä¼šä¸å¯é¢„æµ‹åœ°å¢å¼ºå½¼æ­¤å¯èƒ½å¼•èµ·çš„[å¥å¿˜](/è¯æ•ˆ/å¤±å¿†.md)ã€[é•‡é™](/è¯æ•ˆ/é•‡é™.md)ã€[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)å’Œ[å¦„æƒ³](/è¯æ•ˆ/å¦„æƒ³.md)ã€‚å®ƒè¿˜å¯èƒ½å¯¼è‡´çªç„¶çš„æ„è¯†ä¸§å¤±ï¼Œå¹¶ä¼´æœ‰å±é™©ç¨‹åº¦çš„[å‘¼å¸æŠ‘åˆ¶](/è¯æ•ˆ/å‘¼å¸æŠ‘åˆ¶.md)ã€‚å¦‚æœåœ¨æ„è¯†ä¸§å¤±ä¹‹å‰å‘ç”Ÿ[æ¶å¿ƒ](/è¯æ•ˆ/æ¶å¿ƒ.md)æˆ–å‘•åï¼Œä½¿ç”¨è€…åº”å°è¯•ä»¥[æ¢å¤ä½“ä½](/æ–‡æ¡£/æ¢å¤ä½“ä½.md)å…¥ç¡æˆ–è®©æœ‹å‹å°†å…¶ç§»å…¥è¯¥ä½“ä½ã€‚
* **[å…´å¥‹å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/å…´å¥‹å‰‚.md)** - å…´å¥‹å‰‚ä¼šæ©ç›–[æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)çš„[é•‡é™](/è¯æ•ˆ/é•‡é™.md)ä½œç”¨ï¼Œè¿™æ˜¯å¤§å¤šæ•°äººç”¨æ¥è¡¡é‡å…¶ä¸­æ¯’ç¨‹åº¦çš„ä¸»è¦å› ç´ ã€‚ä¸€æ—¦å…´å¥‹å‰‚ä½œç”¨æ¶ˆé€€ï¼ŒæŠ‘åˆ¶å‰‚çš„ä½œç”¨å°†æ˜¾è‘—å¢åŠ ï¼Œå¯¼è‡´å¼ºçƒˆçš„[å»æŠ‘åˆ¶](/è¯æ•ˆ/å»æŠ‘åˆ¶.md)ã€[è¿åŠ¨æ§åˆ¶ä¸§å¤±](/è¯æ•ˆ/è¿åŠ¨æ§åˆ¶ä¸§å¤±.md)å’Œå±é™©çš„[æ–­ç‰‡çŠ¶æ€](/è¯æ•ˆ/å¤±å¿†.md)ã€‚å¦‚æœä¸å¯†åˆ‡ç›‘æµ‹æ¶²ä½“æ‘„å…¥é‡ï¼Œè¿™ç§ç»„åˆä¹Ÿå¯èƒ½å¯¼è‡´ä¸¥é‡çš„è„±æ°´ã€‚å¦‚æœé€‰æ‹©æ··åˆä½¿ç”¨è¿™äº›ç‰©è´¨ï¼Œåº”ä¸¥æ ¼é™åˆ¶è‡ªå·±åœ¨è¾¾åˆ°æœ€å¤§é˜ˆå€¼ä¹‹å‰æ¯å°æ—¶ä»…æœç”¨ä¸€å®šé‡ã€‚


æ³•å¾‹åœ°ä½
------------

* **ç¾å›½**ï¼šè™½ç„¶ 1,4-ä¸äºŒé†‡ç›®å‰åœ¨ç¾å›½è”é‚¦å±‚é¢æœªè¢«åˆ—ç®¡ï¼Œä½†è®¸å¤šå·å·²å°†å…¶å½’ç±»ä¸ºå—æ§ç‰©è´¨ã€‚æ­¤å¤–ï¼Œä¸ªäººæ›¾æ ¹æ®ã€Šè”é‚¦æ¨¡æ‹Ÿæ³•ã€‹å› è¯¥ç‰©è´¨è€Œè¢«èµ·è¯‰ï¼Œç†ç”±æ˜¯å…¶å®è´¨ä¸Šä¸ GHB ç›¸ä¼¼ã€‚[\[24\]](#cite_note-24) èŠåŠ å“¥è”é‚¦åœ°æ–¹æ³•é™¢è£å®šï¼Œæ ¹æ®è”é‚¦æ³•å¾‹ï¼Œ1,4-ä¸äºŒé†‡ä¸èƒ½è¢«è§†ä¸º GHB çš„ç±»ä¼¼ç‰©ï¼Œç¬¬ä¸ƒå·¡å›ä¸Šè¯‰æ³•é™¢ç»´æŒäº†è¯¥è£å†³ã€‚[\[25\]](#cite_note-25)
* **è‹±å›½**ï¼šåœ¨è‹±å›½ï¼Œ1,4-ä¸äºŒé†‡äº 2009 å¹´ 12 æœˆï¼ˆè¿åŒå¦ä¸€ç§ GHB å‰ä½“ Î³-ä¸å†…é…¯ï¼‰è¢«åˆ—ä¸º C ç±»å—æ§ç‰©è´¨ã€‚
* **å¾·å›½**ï¼š1,4-ä¸äºŒé†‡ä¸æ˜¯ BtMGï¼ˆéº»é†‰å“æ³•ï¼‰æˆ– NpSGï¼ˆæ–°ç²¾ç¥æ´»æ€§ç‰©è´¨æ³•ï¼‰ä¸‹çš„å—æ§ç‰©è´¨ã€‚[\[26\]](#cite_note-26)[\[27\]](#cite_note-27) æ ¹æ® Â§2 AMGï¼Œåªè¦ä¸ä½œä¸ºäººç±»æ¶ˆè´¹å“å‡ºå”®ï¼Œå®ƒå°±æ˜¯åˆæ³•çš„ã€‚[\[28\]](#cite_note-28)
* **åŠ æ‹¿å¤§**ï¼šå®ƒåœ¨åŠ æ‹¿å¤§è¢«åˆ—ä¸ºé™„è¡¨ VI å‰ä½“è¿›è¡Œç®¡åˆ¶ã€‚
* **ç‘å£«**ï¼š1,4-ä¸äºŒé†‡æ˜¯ Verzeichnis E ä¸‹ç‰¹åˆ«æŒ‡åçš„å—æ§ç‰©è´¨ã€‚[\[29\]](#cite_note-29)


å¦è§
--------

* [è´Ÿè´£ä»»çš„ç”¨è¯](/æ–‡æ¡£/è´Ÿè´£ä»»çš„ç”¨è¯ç´¢å¼•é¡µ.md)
* [æŠ‘åˆ¶å‰‚](/æ–‡æ¡£/è¯ç‰©åˆ†ç±»/æŠ‘åˆ¶å‰‚.md)
* [GHB](/è¯ç‰©/GHB.md)
* [GBL](/è¯ç‰©/GBL.md)
* [GABA](/æ–‡æ¡£/GABA.md)


å¤–éƒ¨é“¾æ¥
--------------

* [1,4-Butanediol (Wikipedia)](https://en.wikipedia.org/wiki/1,4-Butanediol)
* [1,4-Butanediol (Erowid Vault)](https://erowid.org/chemicals/14b/14b.shtml)
* [1,4-Butanediol (TiHKAL / Isomer Design)](https://isomerdesign.com/PiHKAL/explore.php?id=12266)


å‚è€ƒæ–‡çŒ®
----------

1. [â†‘](#cite_ref-tripsit_1-0) [*Risks of Combining Depressants - TripSit*](https://tripsit.me/combining-depressants/)Â 
2. [â†‘](#cite_ref-cite_2-0) WHO report on 1,4-butanediol | <https://www.who.int/medicines/areas/quality_safety/4_4_Review.pdf>
3. [â†‘](#cite_ref-3) PubChem, [*1,4-Butanediol*](https://pubchem.ncbi.nlm.nih.gov/compound/8064)Â 
4. [â†‘](#cite_ref-4) Zvosec, D. L., Smith, S. W., McCutcheon, J. R., Spillane, J., Hall, B. J., Peacock, E. A. (11 January 2001). ["Adverse Events, Including Death, Associated with the Use of 1,4-Butanediol"](https://doi.org/10.1056/NEJM200101113440202). *New England Journal of Medicine*. **344** (2): 87â€“94. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1056/NEJM200101113440202](//doi.org/10.1056%2FNEJM200101113440202). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0028-4793](//www.worldcat.org/issn/0028-4793).Â 
5. [â†‘](#cite_ref-5) Zhao, J., Hartwig, J. F. (1 May 2005). ["Acceptorless, Neat, Ruthenium-Catalyzed Dehydrogenative Cyclization of Diols to Lactones"](https://pubs.acs.org/doi/10.1021/om048983m). *Organometallics*. **24** (10): 2441â€“2446. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1021/om048983m](//doi.org/10.1021%2Fom048983m). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0276-7333](//www.worldcat.org/issn/0276-7333).Â 
6. [â†‘](#cite_ref-6) [*Erowid 1,4-butanediol Vault : Storage : 14b and GBL May Dissolve Some Plastics*](https://www.erowid.org/chemicals/14b/14b_storage1.shtml), 2001Â 
7. [â†‘](#cite_ref-7) Carter, L. P., Koek, W., France, C. P. (November 2006). ["Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats: GBL and 1,4-BD after i.p. and i.c.v. administration"](https://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2006.05146.x). *European Journal of Neuroscience*. **24** (9): 2595â€“2600. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1460-9568.2006.05146.x](//doi.org/10.1111%2Fj.1460-9568.2006.05146.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0953-816X](//www.worldcat.org/issn/0953-816X).Â 
8. [â†‘](#cite_ref-8) ["Gamma-Hydroxybutyrate Toxicity: Practice Essentials, Background, Pathophysiology"](https://emedicine.medscape.com/article/820531-overview). 12 May 2022.Â 
9. [â†‘](#cite_ref-9) Burk, M. J., Van Dien, S. J., Burgard, A. P., Niu, W., [*United States Patent: 8067214 - Compositions and methods for the biosynthesis of 1,4-butanediol and its precursors*](https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=8067214.PN.&OS=PN/8067214&RS=PN/8067214)Â 
10. [â†‘](#cite_ref-10) Irwin, R. D. (February 2006). "A review of evidence leading to the prediction that 1,4-butanediol is not a carcinogen". *Journal of applied toxicology: JAT*. **26** (1): 72â€“80. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1002/jat.1110](//doi.org/10.1002%2Fjat.1110). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0260-437X](//www.worldcat.org/issn/0260-437X).Â 
11. [â†‘](#cite_ref-11) Nutt, D., King, L. A., Saulsbury, W., Blakemore, C. (24 March 2007). ["Development of a rational scale to assess the harm of drugs of potential misuse"](https://www.sciencedirect.com/science/article/pii/S0140673607604644). *The Lancet*. **369** (9566): 1047â€“1053. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/S0140-6736(07)60464-4](//doi.org/10.1016%2FS0140-6736%2807%2960464-4). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0140-6736](//www.worldcat.org/issn/0140-6736).Â 
12. [â†‘](#cite_ref-12) [*GHB - Erowid Exp - â€œGHB Overdoses & Poisoningsâ€*](https://www.erowid.org/experiences/exp.php?ID=1926)Â 
13. [â†‘](#cite_ref-13) Zvosec, D. L., Smith, S. W., Porrata, T., Strobl, A. Q., Dyer, J. E. (March 2011). "Case series of 226 Î³-hydroxybutyrate-associated deaths: lethal toxicity and trauma". *The American Journal of Emergency Medicine*. **29** (3): 319â€“332. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.ajem.2009.11.008](//doi.org/10.1016%2Fj.ajem.2009.11.008). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1532-8171](//www.worldcat.org/issn/1532-8171).Â 
14. [â†‘](#cite_ref-14) Sircar, R., Basak, A. (1 December 2004). ["Adolescent Î³-hydroxybutyric acid exposure decreases cortical N-methyl-d-aspartate receptor and impairs spatial learning"](https://www.sciencedirect.com/science/article/pii/S009130570400320X). *Pharmacology Biochemistry and Behavior*. **79** (4): 701â€“708. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pbb.2004.09.022](//doi.org/10.1016%2Fj.pbb.2004.09.022). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0091-3057](//www.worldcat.org/issn/0091-3057).Â 
15. [â†‘](#cite_ref-15) GarcÃ­a, F. B., Pedraza, C., Arias, J. L., Navarro, J. F. (August 2006). "[Effects of subchronic administration of gammahydroxybutyrate (GHB) on spatial working memory in rats]". *Psicothema*. **18** (3): 519â€“524. [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0214-9915](//www.worldcat.org/issn/0214-9915).Â 
16. [â†‘](#cite_ref-16) Sircar, R., Basak, A., Sircar, D. (October 2008). ["Î³-Hydroxybutyric Acid-Induced Cognitive Deficits in the Female Adolescent Rat"](http://doi.wiley.com/10.1196/annals.1432.044). *Annals of the New York Academy of Sciences*. **1139** (1): 386â€“389. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1196/annals.1432.044](//doi.org/10.1196%2Fannals.1432.044). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0077-8923](//www.worldcat.org/issn/0077-8923).Â 
17. [â†‘](#cite_ref-17) Pedraza, C., GarcÃ­a, F. B., Navarro, J. F. (October 2009). ["Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats"](https://academic.oup.com/ijnp/article-lookup/doi/10.1017/S1461145709000157). *The International Journal of Neuropsychopharmacology*. **12** (09): 1165. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1017/S1461145709000157](//doi.org/10.1017%2FS1461145709000157). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1461-1457](//www.worldcat.org/issn/1461-1457).Â 
18. [â†‘](#cite_ref-18) Sircar, R., Basak, A. (December 2004). "Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-D-aspartate receptor and impairs spatial learning". *Pharmacology, Biochemistry, and Behavior*. **79** (4): 701â€“708. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.pbb.2004.09.022](//doi.org/10.1016%2Fj.pbb.2004.09.022). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0091-3057](//www.worldcat.org/issn/0091-3057).Â 
19. â†‘ [19.0](#cite_ref-GHB_19-0) [19.1](#cite_ref-GHB_19-1) GHB Withdrawal Syndrome | Texas Commission on Alcohol and Drug Abuse | <https://www.erowid.org/chemicals/ghb/ghb_addiction2.pdf>
20. [â†‘](#cite_ref-20) Kim, S. Y., Barker, J. C., Anderson, I. B., Dyer, J. E., Earnest, G., Blanc, P. D. (2008). ["Systematic Assessment of Gamma Hydroxybutyrate (GHB) Effects During and After Acute Intoxication"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2759403/). *The American journal on addictions / American Academy of Psychiatrists in Alcoholism and Addictions*. **17** (4): 312â€“318. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1080/10550490802138988](//doi.org/10.1080%2F10550490802138988). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [1055-0496](//www.worldcat.org/issn/1055-0496).Â 
21. [â†‘](#cite_ref-21) Carter, L. P., Pardi, D., Gorsline, J., Griffiths, R. R. (1 September 2009). ["Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (XyremÂ®): differences in characteristics and misuse"](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2713368/). *Drug and alcohol dependence*. **104** (1â€“2): 1â€“10. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1016/j.drugalcdep.2009.04.012](//doi.org/10.1016%2Fj.drugalcdep.2009.04.012). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0376-8716](//www.worldcat.org/issn/0376-8716).Â 
22. [â†‘](#cite_ref-22) Dyer, J. E., Roth, B., Hyma, B. A. (February 2001). "Gamma-hydroxybutyrate withdrawal syndrome". *Annals of Emergency Medicine*. **37** (2): 147â€“153. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1067/mem.2001.112985](//doi.org/10.1067%2Fmem.2001.112985). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0196-0644](//www.worldcat.org/issn/0196-0644).Â 
23. [â†‘](#cite_ref-23) Galloway, G. P., Frederick, S. L., Staggers, F. E., Gonzales, M., Stalcup, S. A., Smith, D. E. (January 1997). ["Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence"](https://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.1997.tb03640.x). *Addiction*. **92** (1): 89â€“96. [doi](http://en.wikipedia.org/wiki/Digital_object_identifier "wikipedia:Digital object identifier"):[10.1111/j.1360-0443.1997.tb03640.x](//doi.org/10.1111%2Fj.1360-0443.1997.tb03640.x). [ISSN](http://en.wikipedia.org/wiki/International_Standard_Serial_Number "wikipedia:International Standard Serial Number")Â [0965-2140](//www.worldcat.org/issn/0965-2140).Â 
24. [â†‘](#cite_ref-24) [*United States of America, Appellee, v. Thomas William Washam, Appellant, 312 F.3d 926 (8th Cir. 2003)*](https://law.justia.com/cases/federal/appellate-courts/F3/312/926/608696/)Â 
25. [â†‘](#cite_ref-25) United States v. Turcotte, 405 F.3d 515 (7th Cir. 2005) "With specific regard to 1,4-butanediol, the jury has returned a special verdict which states that 1,4-butanediol is not a Schedule I drug analogue, because 1,4-butanediol's chemical structure is not significantly similar to the chemical structure of GHB.
26. [â†‘](#cite_ref-26) BtMG | <http://www.gesetze-im-internet.de/btmg_1981/BtMG.pdf>
27. [â†‘](#cite_ref-27) NpSG | <https://www.gesetze-im-internet.de/npsg/NpSG.pdf>
28. [â†‘](#cite_ref-28) [*Â§ 2 AMG - Einzelnorm*](https://www.gesetze-im-internet.de/amg_1976/__2.html)Â 
29. [â†‘](#cite_ref-29) ["Verordnung des EDI Ã¼ber die Verzeichnisse der BetÃ¤ubungsmittel, psychotropen Stoffe, VorlÃ¤uferstoffe und Hilfschemikalien"](https://www.admin.ch/opc/de/classified-compilation/20101220/index.html) (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020.
